Cybin Corp Announces Partnership with the Toronto Centre for Psychedelic Science

Cybin Corp Announces Partnership with the Toronto Centre for Psychedelic Science

TORONTO--(BUSINESS WIRE)--Cybin, Canada's premier medicinal mushroom life sciences company with a core focus on advancing psilocybin research and intellectual property is pleased to announce a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS).

Some of the first academic research available on microdosing was published by the Toronto Centre for Psychedelic Science (TCPS) via its co-founders, Rotem Petranker and Thomas Anderson. Both gentlemen have also been appointed as exclusive clinical advisors to Cybin and will be working alongside the company on all Canadian clinical initiatives.

Cybin is working towards building a vast intellectual property portfolio. The IP is structured around unique psilocybin delivery mechanisms that target certain indications. Key partnerships with esteemed individuals and institutions who share the same vision will assist in the acceleration of Cybin's goals.

"While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach," says Paul Glavine, CEO of Cybin. "We are delighted to join the Centre on this journey," Glavine adds.

"We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigour and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad," says Thomas Anderson, Co-founder of the Toronto Centre for Psychedelic Science.

“I am excited for this collaboration, which will explore the huge potential for benefiting mankind," says Rotem Petranker, Co-founder of the Toronto Centre for Psychedelic Science.

About Cybin Corp

Cybin Corp is a Mushroom Life Sciences company advancing psychedelic and medicinal mushroom research, product development and IP through a multi-tiered pharmaceutical and nutraceutical approach.

The company is launching psilocybin-based products in jurisdiction’s where the substance is not banned alongside structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships.

About Rotem Petranker

Associate Director and co-founder of the Psychedelic Studies Research Program (PSRP) at the University of Toronto

Co-Founder of the Toronto Centre for Psychedelic Science which has published some of the first academic research on microdosing

BSc in psychology from the University of Toronto and an MA in social psychology from York University while currently undergoing his PhD candidacy at York University

Main research interests include sustained attention, emotion regulation and creativity which are ostensibly affected by psychedelics. Clinical interests include disorders amenable to psychedelic psychotherapy, including mood disorders and obsessive compulsive disorder

Rotem is passionate about establishing a rigorous framework for the study of psychedelics using the principles of Open Science

About Thomas Anderson

Research Director and co-founder of the Psychedelic Studies Research Program (PSRP) at the University of Toronto

Co-Founder of the Toronto Centre for Psychedelic Science which has published some of the first academic research on microdosing

PhD candidate and cognitive neuroscientist with the Regulatory and Affective Dynamics (RAD) Lab of Norman Farb, an associate professor of psychology at U of T Mississauga

Thomas’ research is some of the first on psychedelic microdosing

Supported by the Natural Sciences and Engineering Council of Canada (NSERC) and the Stratas Foundation which recently award Thomas with an innovation award

Published scholarly articles on attention, meditation, psychedelics, and neuroimaging and has a strong commitment to open science, rigour, and transparency